Neil Exter, M.B.A., M.S.

  /  

Neil Exter, M.B.A., M.S.

Partner, Third Rock Ventures

Neil Exter is a partner at Third Rock Ventures, which he joined in 2007. At Third Rock, Neil focuses on the formation, development and strategy of new companies. He has more than 30 years of operating, business development and strategy experience across the spectrum of emerging and established biotechnology and technology companies. Neil has held senior operating roles at Constellation Pharmaceuticals, bluebird bio, Foundation Medicine, Pliant Therapeutics, Goldfinch Bio and Cedilla Therapeutics, among others. Prior to joining Third Rock, Neil was chief business officer of Alantos Pharmaceuticals, where he led the sale of the company to Amgen, and earlier, served as vice president for Millennium Pharmaceuticals, directing in-licensing and M&A.

Neil is a member of the investment committee of Mass General Brigham Ventures. Previously, he was a board member and treasurer of the New England Venture Capital Association and a member of the research board at Children’s Hospital.

Neil holds an MBA with highest distinction from Harvard Business School, an M.S. from Stanford University and a B.S. from Cornell University.

Cedilla Therapeutics Announces Appointment of Véronique Riethuisen as Chief Business Officer and Head of Finance

  /  

Cedilla Therapeutics Announces Appointment of Véronique Riethuisen as Chief Business Officer and Head of Finance

CAMBRIDGE, Mass., April 5, 2021 – Cedilla Therapeutics, a venture-backed preclinical biotechnology company developing novel small molecules for cancer and other diseases, today announced the appointment of Véronique Riethuisen as Chief Business Officer and Head of Finance. In this newly created role, Ms. Riethuisen will oversee corporate development, finance and strategic planning and serve as treasurer and company secretary.

“We are thrilled to welcome Véronique to Cedilla. She has an impressive track record shaping and building early and late-stage portfolios for leading biopharmaceutical companies,” said Alexandra Glucksmann, Ph.D., President and Chief Executive Officer of Cedilla Therapeutics. “Véronique’s substantial leadership experience, coupled with her background in corporate and business development, will be instrumental in growing Cedilla. We look forward to her contributions as we execute on our vision of leveraging our novel small molecule drug discovery approach to address the needs of patients with cancer and other diseases.”

“I am honored to join the Cedilla team. Cedilla has developed a novel approach to addressing undruggable targets for the treatment of cancers and diseases caused by protein dysregulation,” said Ms. Riethuisen. “I look forward to working together with my new colleagues to progress a growing portfolio of promising medicines for the benefit of patients.”

Ms. Riethuisen brings over 25 years of experience in global business development, M&A and alliance management leadership to Cedilla. Most recently, Ms. Riethuisen served as Senior Vice President, Global Business Development and Strategic Alliance Management at Ipsen where she helped build Ipsen’s rare disease franchise by acquiring and licensing multiple innovative assets for the treatment of fibrodysplasia ossificans progressiva. She also negotiated Ipsen’s global agreement with Debiopharm for Decapeptyl®, an achievement recognized with the 2020 Award for “Long-Established Alliance” from the Association of Strategic Alliance Professionals. Prior to Ipsen, Ms. Riethuisen was Vice President, Head of Global Transactions at Takeda where she led a team that, in just one year, successfully landed over 20 deals transforming the company’s gastrointestinal and regenerative medicine portfolios. Earlier, Ms. Riethuisen held various business development, M&A and alliance management roles of increasing responsibility at Pfizer, Teva, Bristol Myers Squibb and Monsanto.  Ms. Riethuisen currently serves as an Executive Coach for the MassNextGen program mentoring first-time female chief executive officers, and she teaches a Business Development Fundamentals course annually in conjunction with the BIO Annual Conference. Ms. Riethuisen holds a bachelor and master’s degree in Applied Economics from the University of Brussels (ULB), Belgium.

About Cedilla Therapeutics

Cedilla Therapeutics is a private biotechnology company developing targeted novel small molecule therapeutics directed to unrecognized allosteric binding sites and uncovering novel ways to access key disease drivers. The company employs a target-centric approach and integrates a multidisciplinary set of tools to design novel drug discovery screens that recapitulate the relevant functional state of validated disease drivers that have, to date, eluded conventional therapeutic modalities. For more information, please visit www.cedillatx.com or follow us on LinkedIn.

Investor Contact:

Hannah Deresiewicz
Stern Investor Relations, Inc.
hannah.deresiewicz@sternir.com
212-362-120

Jack Taunton, Ph.D.

  /  

Jack Taunton, Ph.D.

Jack Taunton has spent much of his career developing biochemical tools to illuminate cellular processes relevant to cancer and autoimmune diseases. His work designing covalent inhibitors that target protein kinases led to a drug candidate that’s now advancing through clinical trials. He also discovered a family of cyclic depsipeptides that represent a promising new class of oncology drugs. Jack earned his Ph.D. in chemistry from Harvard University and is a co-founder of Global Blood Therapeutics, Principia Biopharma and Kezar Life Sciences.

William Kaelin, Jr., M.D.

  /  

William Kaelin, Jr., M.D.

Bill Kaelin’s distinguished research career has focused on the proteins encoded by tumor suppressor genes and how mutations in those genes cause cancer. His work on the VHL protein delivered new insights into how cells respond to changes in oxygen levels – and motivated the successful clinical testing of VEGF inhibitors, which are now approved to treat kidney cancer. A professor at the Dana-Farber Cancer Institute and Harvard Medical School, Bill brings deep expertise in the regulation of oncoproteins to Cedilla. He also brings a unique cell-based assay that quickly screens cells to find upstream regulators that control the stability of proteins. Bill has won many top scientific honors, including the Nobel Prize in medicine or physiology, the ASCO Science of Oncology Award, the Canada Gairdner International Award and the Albert Lasker Award for Basic Medical Research. He sits on the editorial board of numerous journals, including Cancer Cell, and has served on the National Cancer Institute’s Board of Scientific Advisors. Bill received his M.D. from Duke University

Matthew Jacobson, Ph.D.

  /  

Matthew Jacobson, Ph.D.

Matt Jacobson is a veteran researcher and entrepreneur with deep experience in both molecular biophysics and drug discovery. A professor at the University of California, San Francisco School of Pharmacy, Matt focuses on research including predicting protein function and regulation, creating new methods for computer-aided drug design and investigating new approaches to treating neurodegenerative diseases.  Matt, who earned his Ph.D. in physical chemistry from MIT, is also a co-founder of Circle Pharma, Relay Therapeutics and Global Blood Therapeutics. He serves on the scientific advisory board of Schrodinger LLC.

Steve Gygi, Ph.D.

  /  

Steve Gygi, Ph.D.

Steve Gygi brings a deep expertise in mass spectrometry and proteomics, with a particular focus on detecting and quantifying the changes that ensue after a protein is perturbed by an external event, such as pharmacological or pathological intervention. A professor of cell biology at Harvard Medical School, Steve specializes in developing technologies for rapid, sensitive and multifaceted analysis of proteins. His lab co-published a protein interaction network, the BioPlex, that includes more than 9,000 proteins. Steve received his Ph.D. in pharmacology and toxicology from the University of Utah.

Alan D’Andrea, M.D.

  /  

Alan D’Andrea, M.D.

Alan D’Andrea brings years of research insights into DNA repair pathways, oncoproteins and ubiquitin to Cedilla. A professor of radiation oncology at Harvard Medical School, Alan also serves as director of the Center for DNA Damage and Repair at Dana-Farber Cancer Institute. Alan’s research centers on the molecular signaling pathways that regulate the cellular response to DNA damage, with a particular focus on the pathogenesis of human chromosome instability and the identification of novel interacting proteins. Alan is a graduate of Harvard Medical School and a member of the National Academy of Science and the National Academy of Medicine.

Dominik Naczynski, PhD

  /  

Dominik Naczynski, PhD

Dominik Naczynski, Ph.D., joined Boxer Capital, LLC in 2014. As Senior Vice President, Dr. Naczynski is responsible for conducting due diligence of public and private investments in healthcare. In his role, he also serves as a Member of the Board of Directors for Cedilla Therapeutics, Inc. Dr. Naczynski received a Bachelor of Science degree in Chemical Engineering from Cornell University and a Ph.D. in Chemical Engineering from Rutgers University. He completed his postdoctoral training in radiation oncology at the Stanford University School of Medicine where his research focused on the application of novel nanomaterials for molecular imaging of cancer. He was also a graduate of the Ignite Program in the Stanford Graduate School of Business.  He has authored and been the recipient of research grants from the National Institutes of Health, National Cancer Institute, and Department of Defense.  He has also published in leading scientific journals and is listed as a co-inventor on several medical device patents.

Rosana Kapeller, M.D., Ph.D.

  /  

Rosana Kapeller, M.D., Ph.D.

Rosana Kapeller is the co-founder, CEO and president of ROME Therapeutics and a fellow at GV (formerly Google Ventures), focused on the intersection of therapeutics and machine learning. In her former role as the founding CSO at Nimbus Therapeutics, Rosana led the company’s drive to apply advanced computational technologies to the design and development of novel therapeutics. In her eight years at Nimbus, she assembled a strong scientific team that validated the company’s platform and advanced multiple promising programs. Before joining Nimbus, Rosana worked as vice president of research at Aileron Therapeutics. She started her career as a scientist at Millennium Pharmaceuticals, where she advanced through positions of increasing responsibility to director. Rosana has served as an adviser to Atlas Venture and has a consultant to Third Rock Ventures. She holds a Ph.D. in molecular and cellular physiology from Tufts University and a M.D. from Universidade do Estado do Rio de Janeiro in Brazil.

Brian Jones, Ph.D.

  /  

Brian Jones, Ph.D.

Chief Scientific Officer

Brian Jones has more than 25 years of drug discovery experience and has led the molecular discovery behind more than 20 INDs across several therapeutic areas. Most recently he spent 11 years at Novartis, where he was head of discovery chemistry for NIBR in Cambridge, Mass. Prior to that, Brian was at Merck for 16 years, initially as director of medicinal chemistry in Rahway, N.J. and subsequently as senior director at the Neuroscience Research Centre in the UK. Brian holds a Ph.D. in chemistry from Imperial College, London. He was a NATO post-doctoral fellow at Yale University.